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Abstract
Background: Adenoviral based vectors remain promising vaccine platforms for use against numerous pathogens, including
HIV. Recent vaccine trials utilizing Adenovirus based vaccines expressing HIV antigens confirmed induction of cellular
immune responses, but these responses failed to prevent HIV infections in vaccinees. This illustrates the need to develop
vaccine formulations capable of generating more potent T-cell responses to HIV antigens, such as HIV-Gag, since robust
immune responses to this antigen correlate with improved outcomes in long-term non-progressor HIV infected individuals.
Methodology/Principal Findings: In this study we designed a novel vaccine strategy utilizing an Ad-based vector
expressing a potent TLR agonist derived from Eimeria tenella as an adjuvant to improve immune responses from a [E1-]Ad-
based HIV-Gag vaccine. Our results confirm that expression of rEA elicits significantly increased TLR mediated innate
immune responses as measured by the influx of plasma cytokines and chemokines, and activation of innate immune
responding cells. Furthermore, our data show that the quantity and quality of HIV-Gag specific CD8
+ and CD8
2 T-cell
responses were significantly improved when coupled with rEA expression. These responses also correlated with a
significantly increased number of HIV-Gag derived epitopes being recognized by host T cells. Finally, functional assays
confirmed that rEA expression significantly improved antigen specific CTL responses, in vivo. Moreover, we show that these
improved responses were dependent upon improved TLR pathway interactions.
Conclusion/Significance: The data presented in this study illustrate the potential utility of Ad-based vectors expressing TLR
agonists to improve clinical outcomes dependent upon induction of robust, antigen specific immune responses.
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Introduction
Although vaccines have provided the greatest impact on human
health and disease, conventional vaccine technologies cannot elicit
the robust immune responsesrequired to eradicate someof the most
pathogenic diseases to affect humanity, such as HIV-AIDS. Clearly,
new paradigms that increase the potency of currently utilized
vaccine platforms are required before diseases like HIV-AIDS can
be treated or prevented. It is now proven that in humans,
Adenovirus (Ad) based vaccines can induce potent cellular immune
responses to HIV derived antigens (as compared to DNA or other
virus based vaccine platforms) but that these responses do not reach
the levels noted in so called long-term non-progressors [1,2].
We, and others, have confirmed that the ability of Ad-based
vaccines to induce innate and adaptive immune responses to Ad-
expressed antigens is mediated by MyD88 and TRIF dependent
intracellular signaling pathways [3,4,5,6]. Since innate immune
responses can dictate the quality of downstream adaptive immune
responses, we have begun to explore the possibility of improving
Ad-based vaccine efficacy by simultaneously enhancing toll-like
receptor (TLR) pathway activation [7].
Relative to treatments with individual TLR ligands, exposure of
sentinel cells of the innate immune system to combinations of TLR
ligands results in synergistic inductions of pro-inflammatory factors
such as IL-12p70, TNFa and type I IFNs (IFNa and IFNb) [8].
This synergism can lead to increased activation of cytolytic cells,
such as NK cells as but one example [9]. In addition to heightened
innate immune responses, the addition of multiple innate receptor
agonists in vaccine formulations can enhance the efficacy of
pathogen or cancer cell specific humoral and cellular immune
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based vaccine platforms with potent TLR ligands may result in a
synergistic improvement in the induction of adaptive immune
responses to Ad-vaccine expressed antigens.
One such potent TLR agonist is an Eimeria tenella expressed
antigen, originally isolated based upon its ability to induce high
levels of IL-12 in bovine intestine [11]. The gene encoding
recombinant E.tenella antigen (rEA; NCBI Accession: AY745810),
was first cloned from E.tenella oocyst mRNA [11,12]. In a murine
model, intra-peritoneal (i.p.) injection of purified rEA protein
resulted in a dramatic induction of Th1 cytokines at 6 hours post
injection (hpi) [11]. Additionally, in vitro studies showed that
enhanced target cell killing was induced following treatment of
NK-cell enriched splenocytes with rEA protein [11]. In vivo,
purified rEA protein has illustrated the potential to increase
protective immunity in animal models, and trigger innate immune
responses in human clinical trial subjects [13,14]. For these
reasons, we hypothesized that expression of rEA from an Ad-based
vector would generate significantly heightened innate responses
leading to more robust adaptive immune responses against
antigens expressed from the vaccine platform. In this study, we
confirm that an Ad-based vector expressing rEA can generate
stronger cellular immune responses to co-expressed or co-
administered antigens than that generated by conventional Ad-
based vaccines.
Results
Incorporation of rEA into an Ad-Vector Induces Enhanced
Innate Immune Responses In Vivo
We first sought to determine if co-injection of both the TLR
agonist protein rEA with an Ad-based vector would synergistically
induce heightened cytokine and chemokine responses as compared
to either treatment alone following intravenous administration, a
common strategy used to characterize Ad-induced innate immune
responses in vivo. To accomplish this, we co-administered 1 ng of
purified rEA protein with 7.5610
10 vps of Ad-GFP, and compared
the ensuing cytokine and chemokine responses to those generated
in mice injected with either Ad-GFP or rEA alone (Figure 1). At 6
hpi, serum levels of IL-4, IL-6, IL-12(p70), IL-13, G-CSF, and
MIP-1a were significantly induced over background levels only in
mice injected with both Ad-GFP and purified rEA protein
(p,0.05). Furthermore, serum levels of IL-10, MCP-1, RANTES
and IL-12(p40) were significantly higher in mice injected with both
rEA and Ad-GFP when compared to those administered either
treatment alone (p,0.05).
To determine if rEA expressed from an Ad vector might
synergistically provoke a similar response, plasma cytokine and
chemokine levels were measured following intravenous injection of
a novel rEA expressing vector, Ad-GFP/rEA (Figure 1; Figure
S1A). Interestingly, at 6 hpi, we found that all plasma cytokines
and chemokines tested were induced to higher levels with Ad-
GFP/rEA than with either treatment alone or in combination
(p,0.05) with the exception of KC and IL-12(p40); although a
similar trend was still observed in these latter cytokines.
It has recently been shown that the release of both IL-12 and
IFNc following rEA treatment requires the TLR adaptor protein
MyD88 [15]. To evaluate the potential role for TLR signaling in
mediating the enhanced innate immune responses observed after
Ad-GFP/rEA injection, we also completed an identical experi-
ment in mice genetically deficient in MyD88. The resulting data
show that only slight inductions of IL-12 at 1 and 6 hpi, MCP-1 at
1 hpi, and RANTES at 6 hpi, occurred in the Ad-GFP/rEA
injected MyD88-KO mice, elevations that were insignificant
relative to the robust rEA induced responses we noted in similarly
treated wild-type C57BL/6 mice (Figure S1B). These data confirm
that MyD88 mediated TLR signaling is at least partially, if not
completely, required for the robust innate immune responses
noted shortly after injection of Ad-GFP/rEA.
The rapid induction of these innate factors correlated with the
transcription of the Ad transduced rEA gene within 6 hours of
vector administration (Figure S2). It is noteworthy that we also
detected higher levels of GFP encoding RNA as well as GFP
protein in both the liver and the spleen of Ad-GFP/rEA injected
mice as compared to control mice. In contrast, similarly
heightened levels of GFP specific RNA transcripts or protein
were not observed in MyD88-KO mice identically injected with
the Ad-GFP/rEA virus. Known NFkB binding sites within the
CMV promoter/enhancer region may explain this result; i.e. rEA
induced, MyD88 dependent induction of NFkB activity may result
in increased transcription of CMV driven transgenes [16].
Importantly, the robust innate immune response elicited by Ad-
GFP/rEA was attenuated when the virus was UV-inactivated
(rendering GFP and rEA expression nearly undetectable) prior to
injection (Figure S2, S3). This indicates that de novo expression of
rEA was primarily responsible for the observed results.
Other measures of Ad induced innate immune responses
revealed that thrombocytopenia was significantly greater at both
1 and 3 dpi (p,0.01) in mice treated with Ad-GFP/rEA as
compared to control mice (Figure S4A). However, the kinetics of
systemic ALT elevations were not significantly different between
the Ad-GFP and the Ad-GFP/rEA treated mice (Figure S4B).
Ad-Vectors Expressing rEA Induce Enhanced Innate
Immune Cell Activation
The activation of NK cells has been shown to occur subsequent
to Ad administrations, as well as recombinant rEA protein
injections [11,17]. Our results confirm that at 6 hpi, both Ad-
based vectors and purified rEA protein individually induced a
rapid activation of splenic NK and NKT cells as measured by the
increase in percentage of these cell types that express the
lymphocyte activation marker CD69 (data not shown). However
co-administration of both the Ad-vector and purified rEA protein
did not result in a synergistic induction of CD69 on the surface of
either NK or NKT cells derived from the spleen (data not shown).
More impressively, our data show that expression of rEA from the
Ad-GFP/rEA vector not only resulted in a significant increase in
the percentage of CD69 positive NK and NKT cells present in
both the liver and the spleen (p,0.05) (Figure 2A and B), but also
indicated that the per cell expression of CD69 (as measured by the
mean fluorescence intensity (MFI)) is also significantly higher on
the surface of both NK and NKT cells in the spleen, as well as
NKT cells in the liver (p,0.01). After Ad-GFP control vector
treatment, we observed a significant decrease in the total
population of NK cells in the spleen that coincided with a
significant increase of NK cells in the liver while the total NKT cell
population decreased in both the liver and the spleen (Figure S5A).
No significant differences in NK/NKT cell distribution were
observed between Ad-GFP and Ad-GFP/rEA injected mice.
It has been shown that administration of rEA protein can induce
heightened DC activation and maturation in vitro which results in
the release of both IFNc and IL-12 [18]. Furthermore, numerous
TLR agonists have been shown to increase the expression of MHC
class II molecules on antigen presenting cells (APCs) [19]. Although
we found a statistical increase in the percentage of MHC-II
expressing Cd11b+ (a macrophage marker) splenocytes in mice
injected with both Ad-GFP and rEA protein as compared to mock
injected mice, no statistical differences in MHC-II expressing
A TLR Ligand Based Ad Vaccine
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co-injected with rEA and Ad-GFP versus those mice injected with
either treatment individually (data not shown). Furthermore, we did
not detect significantly higher percentages of MHC-II+ macro-
phages or DCs in mice injected with Ad-GFP/rEA as compared to
those injected with Ad-GFP (Figure 3 and data not shown).
Both CD80 and CD86 are considered important co-stimulatory
molecules present on DCs that enhance the activation of both B-
cells and T-cells. Therefore we also evaluated the induction of
both of these factors on the surface of DCs (Cd11c
High, Cd11b-)
derived from the spleens of Ad-GFP or Ad-GFP/rEA injected
mice. Our results confirm that both CD80 and CD86 co-
stimulatory molecules are induced by injection of Ad-based vectors
alone, and that expression of rEA from Ad-GFP/rEA results in a
significant increase in the percentages of splenic DCs expressing
these factors when compared to mice identically treated with Ad-
GFP (p,0.001) (Figure 3). Furthermore MFI analyses indicate
that the per cell expression of both CD80 and CD86 is also
significantly higher on the surface of CD11c+, Cd11b- splenocytes
derived from Ad-GFP/rEA injected mice (p,0.001). We also
observed a dramatic shift in the Cd11b/Cd11c expressing
splenocyte population following Ad-vector injections. Specifically,
whereas the population of Cd11c+ cells significantly increased
(from 5% to .35%), the percentage of splenocytes expressing
Cd11b significantly decreased (from 15% to ,5%) likely due to
the migration and/or destruction of Ad infected Cd11b+ and
Cd11c+ APCs in the spleen (Figure S5B).
An rEA Expressing Ad Vector Can Generate Improved
T-Cell Responses to Co-Expressed Antigenic Targets
To determine if purified rEA protein mixed with the Ad-Gag
vaccine could serve as an adjuvant to induce improvements in Gag
specific cellular mediated immune (CMI) responses, C57BL/6 and
Balb/c mice were injected IM with Ad-Gag 6 various doses of
purified rEA protein (1, 10, or 100 ng) (Figure S6). At 14 dpi,
splenocytes were isolated from vaccinated animals and exposed
to known immunodominant Gag peptides to recall a memory
response ex vivo. We did not observe improved CMI responses in
Figure 1. Heightened Ad-GFP/rEA induced cytokine responses. (A) C57BL/6 mice were mock injected (n=4), or IV injected with 7.5610
10 vps
of Ad-GFP, 1 ng purified rEA protein, a mix of Ad-GFP and rEA protein, or Ad-GFP/rEA. Plasma was harvested and cytokines and chemokines were
measured at 6 hpi (n=5-10). Bars represent mean 6 SE. #, ## represent significantly different from mock injected animals (p,0.05, p,0.01
respectively). *,**, *** represent statistical differences (p,0.05, p,0.01, p,0.001, respectively). ns, not significant.
doi:10.1371/journal.pone.0009579.g001
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tested (Figure S6). In fact, we detected significantly lower Gag
specific CMI responses in Balb/c mice injected with Ad-GFP
+100 ng purified rEA. The reason for such an unexpected effect is
unclear, but has been observed in other model systems in which a
TLR9 CpG agonist was used in combination with an Ad-based
vaccine formulation [20]. A comparison of the plasma cytokine
and chemokine profile in mice injected IM or IP with purified rEA
protein did not reveal significant differences, thus eliminating the
possibility that route of rEA adjuvant injection could partially
explain this response (data not shown).
We next evaluated antigen specific CMI responses generated
against transgenes expressed by conventional, or rEA co-
expressing Ad-vectors. At 7 dpi, mice intravenously treated with
the Ad-GFP/rEA virus demonstrated a significantly higher GFP
specific CMI response when compared to control animals as
measured by IFNc ELISpot analyses (p,0.01) (Figure 4A). Similar
results were obtained after intramuscular vaccinations (p,0.01)
(Figure 4B). Importantly, these results indicate that an Adenovirus
vector expressing a TLR agonist such as rEA has a superior ability to
enhance antigen specific CMI responses in vivo relative to co-
administration of purified TLR agonist proteins.
To determine if an Ad expressing rEA could facilitate improved
adaptive immune responses to pathogen specific antigens, we
evaluated the induction HIV-Gag antigen specific CMI responses
in splenocytes harvested from C57BL/6 mice co-immunized with
equivalent particle numbers of an Ad-based vaccine expressing the
HIV-1 clade B Gag protein mixed with either Ad-GFP, or Ad-
GFP/rEA. At 14 dpi, we observed a .100% improvement in
HIV-Gag specific CMI responses when Ad-GFP/rEA was present
(p,0.001) (Figure 5A). Importantly, this improved response was
not observed in MyD88/TRIF double knockout mice confirming
the requirement for MyD88/TRIF dependent TLR pathways in
mediating this response (Figure 5A).
To determine if rEA expression facilitates adaptive immune
responses despite differences in genetic backgrounds, we performed
Figure 2. Ad-GFP and Ad-GFP/rEA induced NK and NKT cell activation in liver and spleen in vivo. C57BL/6 mice (N=3) were either mock
injected or injected with 7.5610
10 vps of either Ad-GFP or Ad-GFP/rEA. Lymphocytes from liver and spleen tissue were harvested at 6 hpi, stained for
expression of surface markers for (A) NK cells or (B) NKT cells and FACS sorted. Bars represent mean 6 SE. #, ##, ### represent significantly
different from mock injected mice (p,0.05, p,0.01 respectively). *,**,*** represent statistical differences (p,0.05, p,0.01, p,0.001, respectively).
Representative contour plots are illustrated at right. ns, not significant; MFI, mean fluorescence intensity.
doi:10.1371/journal.pone.0009579.g002
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significantly moreGag specific CD8
+ T-cellsin PBMC preparations
8 days post vaccination in mice co-injected with the Ad-Gag and
Ad-GFP/rEA vectors using a Gag specific MHC class I tetramer
(Figure 5B). Furthermore, significantly heightened HIV-Gag
specific IFNc expressing T-cells were detected in Ad-GFP/rEA
treated mice at 14 dpi when splenocytes were stimulated ex vivo with
two different HIV-Gag derived peptides (Figure 5C). Following
CD8
+ T-cell depletion,ourresults indicatedthat only 10-30%ofthe
HIV-Gag specific, IFNc secretingcells were CD8
2 inbothC57BL/
6 (Figure 6A) and Balb/c (Figure 6B) mice immunized with Ad-
Gag+Ad-GFP. Interestingly, this ratio was altered in mice co-
vaccinated with Ad-GFP/rEA, where rEA expression facilitated a
more balanced response, manifesting as an increased generation of
greater numbers of CD8
2 cells (most likely CD4
+ T-cells, and/or a
very minor population of NK and/or NKT cells) in the antigen
specific responsive T-cell population.
Ad Vaccines Expressing TLR Agonists Increase the
Breadth of HIV-Gag Specific CMI Responses
Increased breadth of CMI responses has been associated with
improved protection upon pathogenic challenge [21]. To measure
the breadth of the HIV-Gag specific CMI response, we harvested
splenocytes from both C57BL/6 (Figure 7A) and Balb/c
(Figure 7B) mice co-injected with the Ad-Gag and Ad-GFP/rEA
vectors, and stimulated the cells ex vivo with peptide pools each
containing 2-4 HIV-Gag specific overlapping 15mer peptides
spanning the entire HIV-Gag protein sequence. We observed a
dramatic increase in the breadth of the HIV-Gag specific CMI
response induced by utilization of the rEA expressing Ad, as
evidenced by greater numbers of peptide pools activating
splenocytes from Ad-GFP/rEA treated mice. These data indicate
that expression of rEA facilitated the recruitment of greater
numbers of diverse HIV-Gag specific T-cell clones, each reactive
to unique HIV-Gag specific peptides present within the entire
HIV-Gag protein sequence.
To determine if this improved induction of T-cell responses
translated into improvements in antigen specific T-cell effector
functions, we confirmed that Balb/c mice co-vaccinated with the
Ad-GFP/rEA and Ad-Gag vectors have a .80% improvement in
HIV-Gag specific cytotoxic T-cell mediated killing in vivo
(Figure 7C). These data indicate that expression of rEA not only
increases the quality and breadth of several antigen specific CMI
responses, but also facilitates an increased functional capacity of
antigen specific T-cells to kill cells presenting a pathogen specific
peptide, in this instance an antigen derived from the HIV-Gag
protein.
Discussion
Our work, and that of others, suggest that TLR mediated
signaling may be an important reason as to why Ad based vaccines
appear to be superior to other vaccine platforms, especially in
regard to elicitation of antigen specific cellular (T-cell) immune
responses [3,5,6,22]. Building upon these findings, we hypothe-
sized that synergistic manipulation of TLR dependent innate
immune responses may further improve the ability of Ad-based
vaccines to induce beneficial immune responses to pathogen
derived antigens. The mechanism by which TLR agonists function
Figure 3. Ad-GFP and Ad-GFP/rEA induced DC activation in spleen in vivo. C57BL/6 mice (N=3) were either mock injected or injected with
7.5610
10 vps of either Ad-GFP or Ad-GFP/rEA. Lymphocytes from spleen tissue were harvested at 6 hpi, stained for expression of surface markers
Cd11c, Cd11b, CD80, CD86 and MHC-II. CD-19, NK1.1, and CD3 expressing cells were eliminated using PerCP-Cy5.5 labeled antibodies. Cd11c
High,
Cd11b- cells are represented. Bars represent mean 6 SE. #, ##, ### represent significantly different from mock injected mice (p,0.05, p,0.01,
p,0.001 respectively). *,**,*** represent statistical differences (p,0.05, p,0.01, p,0.001, respectively). Representative histograms are found at right.
ns, not significant; MFI, mean fluorescence intensity.
doi:10.1371/journal.pone.0009579.g003
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that enhanced release of co-stimulatory factors (such as pro-
inflammatory cytokines) from antigen presenting cells improves
CD8
+ T cell priming, possibly via facilitation of more efficient
antigen processing and MHC class I and II antigen presentation.
The data presented in this study illustrate that de novo expression of
a TLR agonist, such as rEA, from an Ad-based vector can
dramatically increase the release of co-stimulatory cytokines and
chemokines, the majority of which were TLR system dependent.
These inductions correlated with an increase in DC activation in
the spleen, as well as NK and NKT cell activation in both the liver
and the spleen. The increased activation of these cell types
immediately following Ad-GFP/rEA vaccination likely contribut-
ed to both the increase in population and functionality of antigen
specific cells noted in this study [23,24]. We also observed
enhanced thrombocytopenia following Ad-GFP/rEA administra-
tion, an innate immune response that positively correlated with
other innate immune responses evaluated after administration of
the rEA expressing Ad vector. Importantly, we did not observe an
increase in liver toxicity after IV administration of the rEA
expressing Ad5 vaccine, a result that is in stark contrast to results
we have previously reported following injection of other human
and non-human Ad serotypes currently being considered as
alternative Ad-based vaccine platforms [25].
Most recently, the STEP trial revealed that use of a
conventional Ad5 based vaccine expressing HIV antigens induced
Figure 4. Heightened transgene specific cellular responses as a
resultof Ad-GFP/rEA injection. (A) C57BL/6 mice were mock injected
(n=3) or IV injected with 1610
10 vp of either Ad-GFP or Ad-GFP/rEA
(n=8). Splenocytes were harvested 7 dpi and used to complete IFNc
ELISpot analyses. Spotformingcells(SFCs)arereported. (B) C57BL/6mice
(n=6) were injected IM as above. IFNc ELISpot analyses were completed
at 14 dpi. Bars represent mean 6 SE. ## represent significantly different
from mock injected mice (p,0.01). *,** represent statistical differences
(p,0.01).
doi:10.1371/journal.pone.0009579.g004
Figure 5. Increased HIV-Gag specific CMI responses in mice co-
injected with Ad-GFP/rEA. (A)W i l d - t y p e( N=3 )o rM y D 8 8 / T R I Fd o u b l e
knockout (M88-TRIF DKO; N=3) mice were co-immunized IM with
equivalent viral particles of Ad-Gag mixed with either Ad-GFP or Ad-GFP/
rEA (total of 1610
7 vps mixed prior to injection). At 14 dpi IFNc ELISpot
analyses were completed using QBI# 304796 to restimulate cells ex vivo.
Data are presented as mean 6 SE. *** denotes statistically significant
difference (p,0.001). (B, C) Balb/c mice (n=3) were co-immunized IM as
above (total of 1610
6 vps). At 8 dpi, Gag specific CD3+/CD8+ T-cells in
PBMC preparations were analyzed by FACS. (C)A t1 4d p i ,s p l e n o c y t e sw e r e
stimulated ex vivo w i t ht h ei n d i c a t e dp e p t i d et oc o m p l e t eI F N c ELISpot
analyses. Data represent the mean 6 SE. *, *** represent p,0.05, p,0.001
respectively. This experiment was completed in triplicate at various doses
yielding identical results (two doses are illustrated in this figure).
doi:10.1371/journal.pone.0009579.g005
A TLR Ligand Based Ad Vaccine
PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9579significant HIV specific cellular immune responses, yet the vaccine
failed in preventing HIV infections in vaccinees [26]. Although the
results of the STEP trial were confounded by a low acquisition rate
of HIV by Ad5 immune, placebo treated vaccinees, the data
resulting from this trial could suggest that uncircumcised males
with pre-existing Ad5 immunity may have contracted the HIV
virus at a greater rate than placebo control populations. Ongoing
investigations into the mechanisms behind these latter notions
have been contradictory and include conflicting studies as to
whether or not HIV transmission is also a result of robust CD4+
T-cell responses to the Ad5 vector in Ad5 immune vaccinees
[27,28]. Newly initiated studies utilizing Ad based HIV vaccines in
Ad-naive vaccinees should help clarify these issues.
Recent evidence has suggested that a robust CTL proliferative
response to the HIV-Gag antigen in long term non-progressors
infected with HIV is the most common immune parameter
associated with controlling viral loads [1]. It is therefore possible
that the disappointing outcome in the STEP trial may be correlative
to the conventional Ad vaccine’s sub-optimal elicitation of HIV-
Gag specific T cell responses in vaccinees [26]. Therefore, we
sought to determine if use of an Ad5 vaccine expressing a TLR
agonist could improve immune responses to the HIV-Gag antigen.
The TLRagonist rEA has beenshown inmouseand humanclinical
trials to correlate with functional improvements in the quality of the
innate and/or adaptive immune responses elicited [11,13,14]. Our
experiments confirmed a heightened HIV-Gag specific T-cell
response in PBMC preparations, and a significant improvement
in the numbers, and antigenic breadth of HIV-Gag specific, IFNc
expressing T-cells present in splenocytes derived from animals
treated with both HIV-Gag and TLR agonist (rEA) expressing Ad
vaccines. Most importantly, the qualitative improvements elicited
by Ad mediated expression of rEA positively correlated with an
improved functional capability (CTL activity) of HIV-Gag specific
T-cells in vivo. T-cell depletion studies confirmed that Ad mediated
expression of rEA significantly altered the antigen specific CD4
+/
CD8
+T cellratio,fosteringinductionofamorebalancednumberof
the two antigen specific T-cell subsets in Ad-GFP/rEA treated
animals.
Together, these data indicate that simultaneous expression of
rEA, or potentially other similar TLR ligands from an Ad vector,
can serve to enhance CMI responses to pathogen derived antigens
expressed from either the same, or other Ad-based vectors.
Although we have focused on Ad-based vaccine approaches, this
platform could be expanded to other viral and non-viral vaccine
Figure 6. Ad-GFP/rEA improves antigen specific CD8
+ and CD8
-
cellular responses. At 14 dpi, splenocytes from vaccinated C57BL/6
(1610
7 total vps) (A) or Balb/c (1610
8 total vps) (B) mice were
equivalently pooled (N=3 mice per treatment) and CD8+ cells were
depleted using magnetic beads and IFNc ELISpot analyses were
completed. %SFC that are CD8
-=(#SFCs CD8 dep/#SFCs CD8
+)*100.
This experiment was repeated two independent times with the same
result.
doi:10.1371/journal.pone.0009579.g006
Figure 7. Increased quantity and quality of Gag-specific T-cells
in Ad-GFP/rEA co-injected mice. At 14 dpi, splenocytes from
vaccinated C57BL/6 (1610
7 total vps) (A) or Balb/c (1610
8 total vps) (B)
mice were equivalently pooled (N=3 mice per treatment) and
individual wells were stimulated ex vivo with a pool of 2-4 15-mer
peptides spanning the complete Gag protein sequence, not including
peptides included in Figure 5 (AMQ, or 304796). Inset graphs indicate
the number of wells with .10 SFCs. This experiment was carried out
two independent times with the same result. (C) Balb/c mice were
vaccinated as above (total of 1610
7 vp). At 14 dpi, an in vivo CTL assay
was completed and Gag specific CTL activity was quantified (N=2 for all
treatments). This experiment was carried out two independent times,
each with the same result.
doi:10.1371/journal.pone.0009579.g007
A TLR Ligand Based Ad Vaccine
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protocols including those employing whole organism or subunit
vaccines. Of particular importance, these results confirmed the
efficacy of this regimen in two independent mouse backgrounds
that induce highly divergent immune responses in response to
antigen exposure (i.e.: C57BL/6 mice initiate Th1 responses, while
Balb/c mice initiate Th2 responses), which could be confirmed
using indicator, as well as pathogen derived (e.g.: HIV-Gag)
antigens. Together, these data suggest that this novel platform has
the potential to succeed in multiple genetic backgrounds and
against other diseases amenable to vaccine therapy. Future studies
in higher order animal challenge models will be required to
evaluate the potential for Ads expressing TLR agonists to be used
as improved vaccine vectors. However, the facts presented in this
study suggest that utilization of Ad-based vaccines expressing TLR
agonists may show significantly improved efficacy in human
populations.
Methods
Vector Construction
The Open Reading Frame (ORF) of rEA gene was inserted into
an identical CMV driven cassette directly upstream of the GFP
cassette. The resulting pAdTrack-rEA shuttle with the pAdEasyI
Ad5 vector genome as previously described [29] yielding pAd-
GFP/rEA. HEK293 cells were used to amplify virus. Direct
sequencing and restriction enzyme mapping were carried out to
confirm the integrity of the rEA sequence. A direct comparison of
transduction efficiency was completed for Ad-GFP and Ad-GFP/
rEA virus preparations using flow cytometry. Similar transduction
efficiencies were observed (Figure S7). To construct Ad-Gag, the
HXB2 Gag gene (Genbank Accession #K03455; kindly supplied
by Dr. Frank Jones, Etubics, Corp., originally obtained from NIH
Vaccine Research Center) was sub-cloned from the pvrc3900
plasmid into the pShuttle-CMV plasmid using restriction endo-
nuclease cloning strategies. Restriction digests and sequencing
were used to confirm the sequence integrity of the resulting shuttle
(pShuttle-CMV-HIV-Gag). Recombination and viral propagation
was completed as described previously [30]. Gag expression was
verified using Western blotting (data not shown).
Animal Procedures
All animal procedures were approved by the Michigan State
University Animal Care and Use Committee. Intravenous
injection of animals (2–4 months in age) via the retro-orbital sinus
consisted of virus diluted in 200 ml of PBS (pH 7.4). Intramuscular
injections were completed in a total volume of 20 ml into the
tibialis anterior of the right hindlimb. Adult male C57BL/6 and
Balb/c mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). MyD88-KO, and TRIF-KO mice were kindly
provided by Dr. Shizuo Akira. MyD88/TRIF DKO mice were
bred at Michigan State University. Plasma and tissue samples were
processed at the indicated times post-injection as previously
described [3].
rEA Protein Purification
rEA protein was prepared as previously described with minor
modifications [11]. rEA protein from E. tenella was expressed from
pET Blue1 plasmid in Rosetta2 DE3 pLacI strain of E.coli as
native non-tagged protein. Bacterial growth and IPTG induction
of the gene were optimized according to manufacturer’s
recommendations. Bacterial cells were collected, washed twice
with phosphate-buffered saline (PBS), re-suspended in PBS
supplemented with 4 mM PMSF and disrupted with 5 mg/ml
lysozyme (Worthington, Freehold, NJ) and sonication (Sonifier
Cell Disruptor 350, Branson, Danbury, CT) (15 pulses, 10 sec
each with 1 min intervals on ice) followed by high-speed
centrifugation to remove cell debris. The protein was then purified
from bacterial lysates by a modification of the procedure described
previously [11].
1. Ammonium sulfate (AS) fractionation. Bacterial lysate
was fractionated with AS at 40% (1
st step, rEA in supernatant) and
80% (2
nd step, rEA in pellet) saturation. Final pellet was collected
by high-speed centrifugation.
2. DEAE chromatography. Protein sample was loaded onto
DEAE-Sepharose B in 0.2M NaCl in PBS and eluted in 0.5M
NaCl in PBS.
3. Digestion of nucleic acids. rEA-containing fractions
were treated with a mixture of protease-free RNase A (Boehringer,
Columbus, OH) and DNase I (Roche, Indianapolis, IN), 4 hours
at +4uC, 0.2 mg/ml, and 2 U/ml as final concentrations,
respectively.
4. Re-chromatography on DEAE-Sepharose B as in step 2.
5. Endotoxin removal. The sample was passed through
Endotoxin Removing Detoxi Gel (Pierce, Rockford, IL) 3-4 times.
Removal of endotoxin was followed by two tests: Pyrogent Plus test
(Cambrex Bio Sci., Walkersville, MD) and Pyrochrome test
(Associates of Cape Cod Inc., Falmouth, MA).
rEA protein in final preparation was found to be .95%
homogeneous by SDS-gel electrophoresis and its concentration
was determined by Bradford reagent (Bio-Rad). For mouse
injections the final rEA preparation was diluted in 0.1% human
serum albumin (HSA), in 0.9% saline (USP grade, Abbott Labs,
Abbott Park, IL) and filter-sterilized.
Cytokine and Chemokine Analysis
A mouse multiplex based assay was used to determine the
indicated cytokine/chemokine plasma concentrations per the
manufacturer’s instructions (Bio-Rad, Hercules, CA) via Luminex
100 technology (Luminex, Austin, TX) essentially as previously
described [3].
Isolation of Lymphocytes
Splenocytes were prepared by physical disruption of spleen
tissue, passage of the resulting cell suspension through a 40 mm
sieve, followed by RBC lysis and resuspension in RPMI 1640
supplemented with 10% FBS and penicillin/streptomycin/fungi-
zone. Liver tissue was minced into small pieces, incubated for
1 hour at 37uC with vortexing at 15 min intervals in collagenase/
DNase containing RPMI 1640 supplemented with 10% FBS and
penicillin/streptomycin/fungizone. This was followed by passing
the tissue through a 40 mm sieve followed by RBC lysis and
resuspension in complete RPMI media.
ELISpot Analysis
ELISpot assays were completed per manufacturer’s protocol
using the Ready-set Go IFNc mouse ELISpot kit purchased from
eBioscience (San Diego, CA). 4 mg/ml of GFP, LacZ, or Gag
specific peptides (GFP-DTLVNRIEL; LacZ–DAPIYTNV; Gag-
AMQMLKETI) (Genscript, Piscataway, NJ) were used to stimulate
5610
5 splenocytes/well ex vivo. 15mer Gag specific peptides were
obtained from the NIH AIDS Reagent and Reference Program
Cat# 8117 Lot# 9. Spots were counted using an automated
ELISpot reader system (Cellular Technology, Cleveland, OH).
Cell Staining and Flow Cytometry
Splenocytes were stained with various combinations of the follow-
ing antibodies: PE-CD69 (3 mg/ml), PE-Cy7-NK1.1, APC-CD3 (for
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CD11b, APC-CD80, V450-CD86, Alexa Fluor700-MHC-II,
PerCpCy5.5-CD19, PerCpCy5.5-CD3, and PerCpCy5.5-NK1.1
(for APC activation/maturation) (4 mg / m l )( A l lo b t a i n e df r o mB D
Biosciences, San Diego, CA). Cells were initially incubated with
CD16/32 FcR II/III antibody to minimize nonspecific binding. Cells
were then incubated on ice with the appropriate antibodies for 30
minutes, washed, and sorted using an LSR II instrument and
analyzed using FlowJo software. For APC analysis, NK-, B-, and T
cells were removed from the analysis using PerCpCy5.5-conjugated
CD3, CD19, and NK1.1 antibodies. For tetramer staining, PBMCs
were stained with PE labeled AMQMLKETI tetramer (NIH
Tetramer Core Facility), APC-CD3, and Pacific Blue-CD8a. All
antibodies were purchased from BD Biosciences, San Diego, CA.
CD8
+ cells were depleted from pooled splenocyte preparations using
MACS beads per the manufacturer’s protocol (Miltenyi Biotec,
Bergisch Gladbach, Germany). FACS analyses revealed .96%
depletion of CD8
+ T-cells (Figure S8). All FACS studies were
completed using an LSR II instrument and analyzed using FlowJo
software.
In Vivo CTL Assay
14 days post vaccination of Balb/c mice, syngeneic splenocytes
from Naı ¨ve mice were pulsed with an irrelevant peptide
(NYDNAGTNL) or with the HIV-Gag AMQMLKETI peptide
and stained with 1 mM CFSE (CFSE
Low)o r1 0 mM CFSE
(CFSE
High), respectively. Recipient animals were intravenously
injected with equivalent amounts of both CFSE
Low and CFSE
High
stained cells. Mice were terminally sacrificed 5 hpi, splenocytes
were recovered, and sorted on an LSRII flow cytometer. FlowJo
software was used to determine percentages of CFSE stained
cells. % specific killing=1-((% CFSE
High/% CFSE
Low)immunized/
(% CFSE
High/% CFSE
Low)non-immunized).
Supporting Methods
Additional methods are detailed in Methods S1 which describe
the procedures used to complete the supporting experiments.
Statistical Analysis
Statistically significant differences in innate factors were
completed as follows: 1) ANOVA with a Dunnet’s post hoc test
was applied to determine significant inductions of factors relative
to baseline (mock) values, 2) ANOVA with Neuman-Keuls post
hoc test was applied to Ad-GFP, rEA, and Ad-GFP+rEA groups to
determine if co-administration of both factors resulted in
significantly higher levels of each factor, and 3) ANOVA with
Neuman-Keuls post hoc test was applied to all groups to
determine of expression of rEA from the Ad-GFP/rEA vector
induced statistically higher levels of the factor tested. For ELISpot
analysis, a one way ANOVA was used followed by Neuman-Keuls
post hoc test (P,0.05). GraphPad Prism software was utilized for
statistical analysis.
Supporting Information
Methods S1
Found at: doi:10.1371/journal.pone.0009579.s001 (0.03 MB
DOC)
Figure S1 (A) C57BL/6 mice were injected with 1 ng rEA
purified protein, 7.5610
10 vps Ad-GFP, a mixture of both rEA
and Ad-GFP, or 7.5610
10 vp Ad-GFP/rEA. Plasma was harvested
at 6 hpi and plasma cytokines and chemokines were analyzed. #,
## represent significantly different from mock injected animals
using ANOVA and Dunnet’s post hoc test (p,0.05, p,0.01
respectively). *,** represent statistically significant differences
between data points using ANOVA and Newman-Keuls post
hoc test (p,0.05, p,0.01, p,0.001, respectively). (B) MyD88-KO
mice were injected with either Ad-GFP/rEA (n=3) or UV
inactivated Ad-GFP/rEA (n=1) (7.5610
10 vp). At 1 and 6 h.p.i.,
plasma cytokines and chemokines were analyzed. * represents
statistically significant inductions over mock treated mice (n=3)
using ANOVA and Dunnet’s post hoc test (p,0.05). All bars
represent mean 6 SE.
Found at: doi:10.1371/journal.pone.0009579.s002 (0.14 MB
PDF)
Figure S2 (A) C57BL/6 or MyD88-KO mice were either mock
injected or intravenously injected with 7.5610
10 vp of Ad-GFP, Ad-
GFP/rEA, or UV treated Ad-GFP/rEA. Liver and spleen tissues
were harvested at 6 hpi and analyzed for expression of the GFP
transgene using Western blotting. Tubulin was probed as a loading
control. This experiment was completed in triplicate with similar
results. (B) RNA was also prepared from both liver and spleen tissues
and analyzedforthe presenceofGFP andrEA transcriptusing semi-
quantitative RT-PCR. GAPDH was used as a template control. All
samples were evaluated in triplicate with equivalent results.
Found at: doi:10.1371/journal.pone.0009579.s003 (0.16 MB
PDF)
Figure S3 C57BL/6 mice were mock injected (n=4), or
intravenously injected with 7.5610
10 vp of Ad-GFP, Ad-GFP/
rEA, or Ad-GFP/rEA pre-treated with 800 mws UV radiation
(N=5 per group). Plasma was harvested at 1, and 6 hpi. Cytokine
induction was evaluated using Bio-Plex multiplex bead based
ELISA. Bars represent mean 6 SE. * denotes p,0.05, ** denotes
p,0.01.
Found at: doi:10.1371/journal.pone.0009579.s004 (0.11 MB
PDF)
Figure S4 C57BL/6 mice (n=4-5) were intravenously injected
with 7.5610
10 vp of either Ad-GFP or Ad-GFP/rEA. (A) Blood
platelets were enumerated at 1 and 3 dpi. Data points represent
mean 6 SD. ** represents a significant difference between Ad-
GFP, and Ad-GFP/rEA treatment groups at the indicated time
point (p,0.01) using one way ANOVA followed by a Neuman-
Keuls post hoc test. # denotes a statistically significant decrease
compared to the preceding time point (p,0.05) using a
homoscedastic two tailed t-test. (B) Plasma was analyzed at time
0, as well as 1, 3, 7 and 28 d.p.i, for ALT activity. Data points
represent mean 6 SD.
Found at: doi:10.1371/journal.pone.0009579.s005 (0.09 MB
PDF)
Figure S5 C57BL/6 mice (N=3) were either mock injected or
injected with 7.5610
10 vps of either Ad-GFP or Ad-GFP/rEA.
Lymphocytes from liver and spleen tissue were harvested at 6 hpi,
stained for expression of surface markers for (A) NK cells or NKT
cells and FACSsorted.Barsrepresentmean 6 SE. *,**,***represent
statistical differences compared to mock (p,0.05, p,0.01,
p,0.001, respectively). Representative contour plots are illustrated
at right. Note: the gating strategy for NKT cells appears to miss
significant portions of the NKT cell population in the spleen. To
address this issue, we completed multiple analyses using various
strategies in an attempt to include as much as the NKT cell
population as possible. All strategies yielded equivalent results. (B)
Splenic derived lymphocytes were also separated into the various
indicated populations. Multiple gating strategies were also applied
to the changing Cd11b+ population, each yielding equivalent
results. *** represents a statistical difference from mock (p,0.001).
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PDF)
Figure S6 C57BL/6 mice were vaccinated IM with 1610
7 vps
of Ad-Gag + the indicated doses of either PBS or purified rEA
protein. Balb/c mice were vaccinated with 1610
6 vps +100 ng of
purified rEA protein. (A) Anti Gag specific antibodies were titered
from serum at various dilutions. (B) IFNc or (C) IL-2 ELISpots
were completed to quantify antigen specific T-cell responses.
Found at: doi:10.1371/journal.pone.0009579.s007 (0.11 MB
PDF)
Figure S7 HEK 293 cells were infected with the indicated viral
dilutions. Each virus was normalized to 1610
10 viral particles/ml
prior to dilutions in order to directly compare transduction
efficiencies. At 24 hours post infection, % GFP positive cells were
determined using FACS analysis on an LSRII flow cytometer.
Found at: doi:10.1371/journal.pone.0009579.s008 (0.10 MB
PDF)
Figure S8 Depletion resulted in .96% reduction of CD8+ cells.
The viability of recovered CD8 depleted cells was .92% as
measured by trypan blue viability staining.
Found at: doi:10.1371/journal.pone.0009579.s009 (0.08 MB
PDF)
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